MSP Vaccine Company Gains FDA Approval Update for VAXELIS Hexavalent Combination Vaccine in March 2026

A March 12, 2026 FDA approval letter for VAXELIS signals continued regulatory engagement with one of the more manufacturing-complex combination biologics on the U.S. market, a development that contract manufacturers and QA directors overseeing multi-antigen production should read carefully against their own process validation frameworks. MSP Vaccine Company holds the biologics license for the product under STN 125563.

VAXELIS carries the proper name Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine, six antigen components combined into a single 3-dose series indicated for children from 6 weeks through 4 years of age. The sheer antigen count places this product in a category where sterility assurance, comparability protocols, and lot-release testing demand layered controls well beyond those required for monovalent biologics.

The March 2026 action is the latest in a sequence of FDA correspondence stretching back to December 2018, when the original approval letter and Summary Basis for Regulatory Action were issued. Subsequent approval letters in 2020, 2023, and now 2026 reflect the iterative post-approval supplement activity typical of complex biologics, each cycle potentially touching manufacturing changes, labeling revisions, or facility updates that require full 21 CFR Part 601 compliance review. For QA teams, the cadence of these letters is a practical reminder that combination vaccine dossiers remain live regulatory documents long after initial licensure.

For biologics manufacturers and CDMOs operating under ICH Q10 pharmaceutical quality systems, VAXELIS represents a reference case in managing multi-antigen compatibility, formulation stability across components, and the analytical method validation burden that accompanies each antigen independently. Any manufacturing change affecting even one of the six components can trigger a comparability exercise that spans the full combination product, compressing timelines and elevating documentation requirements across the quality system.

The approved indication remains unchanged: active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b, administered as a 3-dose primary series. The current package insert and patient information documents reflect the approved labeling as of the most recent action.

The full approval history, clinical review, and May 2015 statistical review remain publicly accessible through the FDA biologics license application docket, providing a documented regulatory pathway that manufacturers developing analogous combination vaccines can reference during their own BLA submissions.

Source: FDA Center for Biologics Evaluation and Research (CBER) via FDA.gov Vaccines, Blood and Biologics RSS Feed, July 6, 2026.